Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease

Obesity Research

Volumn 13, Issue 7, 2005, Pages 1180-1186

  Clark, Jeanne M ^a,b,f   Alkhuraishi, Amir R A ^c   Solga, Steven F ^a   Alli, Patricia ^d   Diehl, Anna Mae ^e   Magnuson, Thomas H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bariatric surgery; Liver histology; Morbid obesity; Non alco holic fatty liver disease

Indexed keywords

ADULT; ARTICLE; FATTY LIVER; FEMALE; HUMAN; LIVER DISEASE; MALE; METHODOLOGY; MORBID OBESITY; PATHOLOGY; PHYSIOLOGY; ROUX Y ANASTOMOSIS; STOMACH BYPASS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; ANASTOMOSIS, ROUX-EN-Y; FATTY LIVER; FEMALE; GASTRIC BYPASS; HUMANS; LIVER DISEASES; MALE; OBESITY, MORBID; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 32044451685     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2005.140     Document Type: Article

References (53)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-7.
2. Clark JM, Brancati FL, and Diehl AM. Nonalcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the U.S. population. Gastroenterology. 2001; 120(Suppl 1):A-65.
3. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122:1649-57.
4. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-7.
5. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71-9.
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.
7. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121: 91-100.
8. Crespo J, Fernandez-Gil P, Hernandez-Guerra M, et al. Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis? Obes Surg. 2001;11:254-7.
9. Gholam PM, Kotler DP, Flancbaum LJ. Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg. 2002;12:49-51.
10. Beymer C, Kowdley KV, Larson A, et al. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003;138:1240-4.
11. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664-9.
12. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11: 74-80.
13. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-9.
14. Ratziu V, Bonyhay L, Di M, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485-93.
15. Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36:150-5.
16. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology. 2001;120:669-81.
17. Sugerman HJ. The epidemic of severe obesity: the value of surgical treatment. Mayo Clin Proc. 2000;75:669-72.
18. Sugerman HJ, Kellum JM, Engle KM, et al. Gastric bypass for treating severe obesity. Am J Clin Nutr. 1992;55(2 Suppl): 560S-6S.
19. MacDonald KG Jr, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg. 1997;1:213-20.
20. Balsiger BM, Kennedy FP, Abu-Lebdeh HS, et al. Prospective evaluation of Roux-en-Y gastric bypass as primary operation for medically complicated obesity. Mayo Clin Proc. 2000;75:673-80.
21. Mat-Lean LD, Rhode BM, Forse RA. Late results of vertical banded gastroplasty for morbid and super obesity. Surgery. 1990;107:20-7.
22. MacLean LD, Rhode BM, Nohr CW. Late outcome of isolated gastric bypass. Ann Surg. 2000;231:524-8.
23. Holzbach RT. Hepatic effects of jejunoileal bypass for morbid obesity. Am J Clin Nutr. 1977;30:43-52.
24. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
25. Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004;135:48-58.
26. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222-6.
27. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103-7.
28. Wang RT, Koretz RL, Yee HF Jr. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med. 2003;115:554-9.
29. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647-54.
30. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-74.
31. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-9.
32. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med. 1970;282:829-34.
33. Rozental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis. 1967;12:198-208.
34. Zelman S. The liver in obesity. Arch Intern Med. 1952;90: 141-56.
35. Macdonald RA. Pathogenesis of nutritional cirrhosis. Arch Intern Med. 1962;110:424-34.
36. Vyberg M, Ravn V, Andersen B. Pattern of progression in liver injury following jejunoileal bypass for morbid obesity. Liver. 1987:7:271-6.
37. Styblo T, Martin S, Kaminski DL. The effects of reversal of jejunoileal bypass operations on hepatic triglyceride content and hepatic morphology. Surgery. 1984;96:632-41.
38. Griffen WO Jr, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg. 1977;186:500-9.
39. Buckwalter JA. Clinical trial of jejunoileal and gastric bypass for the treatment of morbid obesity: four-year progress report. Am Surg. 1980;46:377-81.
40. Halverson JD, Zuckerman GR, Koehler RE, et al. Gastric bypass for morbid obesity: a medical-surgical assessment. Ann Surg. 1981;194:152-60.
41. Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion. 1990;47:208-14.
42. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol. 1995;104:23-31.
43. Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery. 1996;119: 261-8.
44. Diehl AM. Cytokines and the molecular mechanisms of alcoholic liver disease. Alcohol Clin Exp Res. 1999;23:1419-24.
45. Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev. 2000;174:160-71.
46. Tilg H, Diehl AM. Mechanisms of disease: cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000:343:1467-76.
47. Murr MM, Balsiger BM, Kennedy FP, et al. Malabsorptive procedures for severe obesity: comparison of pancreaticobiliary bypass and very very long limb Roux-en-Y gastric bypass. J Gastrointest Surg. 1999;3:607-12.
48. Solga SF, Clark JM, Alkuraishe A, et al. Race and comorbid factors predict NAFLD histopathology in severely obese patients. Int J Obes Related Metab Disord. 2005;1:6-11.
49. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893-4.
50. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:519-25.
51. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatalogy. 2003;38:1008-17.
52. Bugianesi E, Marzocchi R, Villanova N, Marchesini G. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol. 2004;18:1105-16.
53. Nonalcoholic steatohepatitis clinical research network. Hepatology. 2003;37:244.